Skip to content

Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension

Association Between Biomarkers and Kidney Function Decline in Patients With Pulmonary Hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06409624
Enrollment
400
Registered
2024-05-10
Start date
2024-05-31
Completion date
2027-12-01
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease, Pulmonary Hypertension

Brief summary

The objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (eGFR) among patients with pulmonary hypertension (PH).

Detailed description

PH is a severe, progressive disease associated with right ventricular dysfunction, right-sided heart failure (HF) and death. Kidney disease is present in approximately 35% of patients with PH, and its presence is associated with an enhanced risk for adverse outcomes, with the risk increasing incrementally with declining kidney function. Poor right ventricular function may increase venous congestion, alter ventricular interdependence, decrease effective cardiac output and activate the renin-angiotensin- aldosterone system, thereby aggravating kidney disease. There is a crucial need to better understand the pathophysiological mechanisms linking the failing right heart and the kidney. To date, diagnostic and prognostic biomarkers of kidney disease in PH are lacking. The objective of this study is to examine the association between urinary and plasma biomarkers and change in eGFR among patients with PH.

Interventions

OTHERNo intervention is planned as part of the study

No intervention is planned as part of the study

Sponsors

University of Giessen
Lead SponsorOTHER
Icahn School of Medicine at Mount Sinai
CollaboratorOTHER
University of Virginia
CollaboratorOTHER
Kerckhoff Klinik
CollaboratorOTHER
Universitätsklinikum Hamburg-Eppendorf
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Inpatients aged ≥18 years * Undergoing right heart catheterization (RHC)

Exclusion criteria

* multifactorial or indeterminate PH, for which no single underlying mechanism could be reliably classified * active tumor disease requiring targeted therapy * inflammatory or autoimmune disease with renal involvement requiring systemic immunosuppressive treatment * unexplained kidney function decline, defined as serum creatinine increase ≥0.5 mg/dL from baseline within the prior 7 days before RHC * Chronic kidney disease with eGFR \<20 ml/min/1.73 m2 * non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload * if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC * prediagnosed glomerulonephritis * polycystic kidney disease * postrenal obstruction * single kidney (functional or anatomical) * solid organ transplantation * anticipated life expectancy of \<12 months * likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant) * pregnancy or possibility of pregnancy in the next 12 months * inability to cooperate with respiratory maneuvers during renal Doppler * refusal to participate * not available for follow-up visits

Design outcomes

Primary

MeasureTime frameDescription
Major adverse kidney eventsBaseline to 12 monthsNumber of patients experiencing ≥q of the individual outcomes of the composite outcome of eGFR decline ≥25%, initiation of dialysis, or kidney-related death
Worsening PH or HFBaseline to 12 monthsNumber of patients experiencing worsening of PH, defined as hospitalization due to acute right heart failure, increase in PH-targeted medication or diuretics (outpatient or inpatient), or worsening of PH as diagnosed by right heart catheterization

Secondary

MeasureTime frameDescription
All-cause mortalityBaseline to 12 monthsNumber of patients experiencing all-cause mortality during follow-up
Kidney function decline12 monthsNumber of patients with 50% decline in eGFR from baseline and the eGFR slope at 12 months
Pulmonary hypertension-related death12 monthsDeath attributed to pulmonary hypertension

Countries

Germany

Contacts

CONTACTFaeq Husain-Syed, MD
faeq.husain-syed@innere.med.uni-giessen.de+49 641 985 42378
CONTACTBirgit Jennert, MLA
birgit.jennert@innere.med.uni-giessen.de+49 641 985 42378
PRINCIPAL_INVESTIGATORFaeq Husain-Syed, MD

University of Giessen

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026